LACNETS/PPA/NIH Regional Conference

Pheo Para Track – Speaker Bios
Click here for the full agenda.
Jaydira Del Rivero, MD, NIH

Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center.  Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR). She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors.

She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer.  Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer & pheo para.

Hans Ghayee, DO, University of Florida

Hans Ghayee, D.O, is an endocrinologist and V.A. Section Chief in the University of Florida College of Medicine in Gainesville, Florida. Dr. Ghayee received his osteopathic medical degree from the University of North Texas Health Science Center at Fort Worth. He did his Internal Medicine Residency at Johns Hopkins University/Sinai Hospital, followed by a fellowship, focusing on metabolism and steroidogenesis at University of Texas Southwestern Medical Center.




John Glod, MD, PhD, NIH

Dr. Glod obtained his M.D. and Ph.D. from the University of Colorado in Denver and trained in pediatrics and pediatric oncology at Cincinnati Children’s Hospital, Johns Hopkins Hospital, and the Pediatric Oncology Branch of the NCI.  Following an fellowship in neuro-oncology at the NCI, Dr. Glod served as faculty in the departments of pediatrics and pharmacology at Rutgers Cancer Institute of New Jersey. Dr. Glod joined the Pharmacology and Experimental Therapeutics Section in 2013.  His research interests focus on understanding the biology of rare pediatric solid tumors and exploring new therapies for patients with these diseases.


Mickey Kuo, MD, NIH

Originally from Austin, Texas, Dr. Kuo completed medical school at the University of Texas Medical Branch in Galveston. He then moved to Chicago, where I completed a combined Internal Medicine and Pediatrics residency program at Loyola University Medical Center, which is also where he met my first patient with pheochromocytoma. To pursue his interests in medical genetics and biomedical research, Dr. Mayank came to NIH in 2019 and has since completed training in Medical Genetics and Genomics as well as Medical Biochemical Genetics. He joined Dr. Pacak’s research group in 2021 due to my interest in the genetic and biochemical underpinnings of pheochromocytoma and paraganglioma.


Erik Mittra, MD, PhD, Oregon Health & Science University

Dr. Mittra is a Professor of Diagnostic Radiology at Oregon Health & Science University (OHSU) where he serves as Chief of the Molecular Imaging and Therapy Section and Director of the Targeted Radiopharmaceutical Therapy Program.

Dr. Mittra received his medical and graduate degrees through the MD/PhD program at Stony Brook University. His post-graduate training included an internship at Stony Brook University, followed by a residency and fellowship in Nuclear Medicine at Stanford University where he was faculty for many years before moving to OHSU.  Dr. Mittra is interested in all aspects of nuclear medicine with a focus on targeted radiopharmaceutical therapies. His research interests are focused on the translation of novel radioisotopes for imaging and therapy. He is involved with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and the North American Neuroendocrine Tumor Society (NANETS), among others.

Naris Nilubol, MD, FACS, NIH

Dr. Nilubol graduated from Chulalongkorn University Medical Center, Bangkok, Thailand with honors. He completed a surgical research fellowship followed by general surgery training in 2005 at The Mount Sinai Hospital, New York, NY. Following surgery residency, Dr. Nilubol completed the Endocrine Oncology Surgery fellowship at Rush University Medical Center, Chicago, IL. Dr. Nilubol was on faculty at Mount Sinai Hospital, NY, before being recruited to NCI. There are over 140 peer-reviewed publications and several book chapters that Dr. Nilubol has authored.


Karel Pacak, MD, PhD, DSc, NIH

Dr. Pacak is a board-certified endocrinologist and an internationally recognized expert in the diagnosis and treatment of neuroendocrine tumors, especially pheochromocytoma and paraganglioma.  He graduated summa cum laude from Charles University, Prague, Czech Republic in 1984. In 1990, he began his postdoctoral fellowship at NINDS. In 1995, Dr. Pacak began his residency in internal medicine at the Washington Hospital Center under Dr. L. Wartofsky, followed by a fellowship in endocrinology, diabetes, and metabolism at NIH. In 1998, he established a new Program for Neuroendocrine Tumors focusing on pheochromocytoma and paraganglioma at NICHD. He received his Ph.D. in 1993 and his D.Sc. in 1998 in the field of neuroendocrinology from Charles University. In 2006, he was awarded a lifetime professorship in Internal Medicine at Charles University.

Dr. Pacak established the International Symposia on Pheochromocytoma. He also helped co-found a new Asian Alliance for the Study of Neuroendocrine Tumors in 2010. He is a recipient of numerous awards including the Peter Heimann Memorial Award at Yale University, International Association of Endocrine Surgeons; NIH Director’s Mentor Award, Award for Cure from Pheo Para Alliance, NICHD Director’s Award of Merit, Pincus Taft Memorial Lecture the Highest Award from Endocrine Society of Australia, and Jessenius Gold Medal from Slovak Academy of Sciences. Dr. Pacak is the author of more than 305 scientific peer-reviewed articles, 98 book chapters, and 5 books.

Mayank Patel, MD, NIH

Mayank Patel is an Anatomical Pathology Resident at the National Cancer Institute. He is dedicated to patient driven research and strives to be the physical interface between the pathology of the condition and the patient. Mayank graduated with a medical degree from American University of Antigua and continues to improve the care of Pheo Para patients through research with Dr. Karel Pacak.


Heloisa Soares, MD, PhD, University of Utah

Dr. Heloisa Soares is a medical oncologist with a focus in GI and neuroendocrine cancers. She is an associate professor at the Huntsman Cancer Institute (HCI) at University of Utah. Dr. Soares received her medical degree at Faculdade de Medicine do ABC in Brazil, where she was born. She completed her residency training at the Mount Sinai Medical Center of Florida and her hematology-oncology fellowship training and PhD in molecular biology at UCLA. Dr. Soares has neuroendocrine tumors and gastrointestinal (GI) cancers as the major focus of her research and clinical activities. She serves as the Medical Director for the Clinical Trials Office as well as the co-physician leader in the GI Clinical Trials Research Group at HCI. In 2019, she was elected as a member of the board of directors for The North American Neuroendocrine Tumor Society (NANETS). Additionally, she is a member of the NCI NET taskforce and member of SWOG and NRG cooperative groups. She is also a panel member for the Neuroendocrine and Adrenal Tumors NCCN Clinical Practice Guidelines in Oncology.